These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12926151)

  • 1. Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy.
    Nather A; Mayerhofer K; Grimm C; Hefler L; Leodolter S; Obermair A; Joura EA
    Anticancer Res; 2003; 23(3C):2991-4. PubMed ID: 12926151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombocytosis in advanced epithelial ovarian cancer.
    Soonthornthum T; Suraseraneewong V; Kengsakol K; Wijaithum K; Kasemsan P; Prommatt S
    J Med Assoc Thai; 2007 Aug; 90(8):1495-500. PubMed ID: 17926975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of anaemia at different treatment times in patients with locally advanced head and neck cancer treated with surgery and postoperative radiotherapy.
    Dietl B; Marienhagen J; Schäfer C; Kölbl O
    Clin Oncol (R Coll Radiol); 2007 May; 19(4):228-33. PubMed ID: 17433968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of platelet count in patients with renal cell carcinoma.
    Erdemir F; Kilciler M; Bedir S; Ozgok Y; Coban H; Erten K
    Urol Int; 2007; 79(2):111-6. PubMed ID: 17851278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytosis in women with vulvar carcinoma.
    Lavie O; Comerci G; Daras V; Bolger BS; Lopes A; Monaghan JM
    Gynecol Oncol; 1999 Jan; 72(1):82-6. PubMed ID: 9889035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet Count After Chemotherapy is a Predictor for Outcome for Ovarian Cancer Patients.
    Eggemann H; Ehricke J; Ignatov T; Fettke F; Semczuk A; Costa SD; Ignatov A
    Cancer Invest; 2015 May; 33(5):193-6. PubMed ID: 25831456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of thrombocytosis in ovarian cancer.
    Słabuszewska-Jóźwiak A; Dmoch-Gajzlerska E; Kozakiewicz B; Jakiel G
    Ann Agric Environ Med; 2015; 22(4):731-5. PubMed ID: 26706987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.
    Suppiah R; Shaheen PE; Elson P; Misbah SA; Wood L; Motzer RJ; Negrier S; Andresen SW; Bukowski RM
    Cancer; 2006 Oct; 107(8):1793-800. PubMed ID: 16983701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer.
    Bozkurt N; Yuce K; Basaran M; Kose F; Ayhan A
    Obstet Gynecol; 2004 Jan; 103(1):82-5. PubMed ID: 14704249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
    Downs LS; Judson PL; Argenta PA; Ghebre R; Geller MA; Bliss RL; Boente MP; Nahhas WA; Abu-Ghazaleh SZ; Chen MD; Carson LF
    Cancer; 2008 Jan; 112(2):331-9. PubMed ID: 18058810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The prognostic value of thrombocytosis in patients with primary lung cancer].
    Pedersen LM; Milman N
    Ugeskr Laeger; 1998 Jun; 160(26):3917-20. PubMed ID: 9656833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
    Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
    Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
    Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
    Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
    McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
    Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma.
    Brockmann MA; Giese A; Mueller K; Kaba FJ; Lohr F; Weiss C; Gottschalk S; Nolte I; Leppert J; Tuettenberg J; Groden C
    Neuro Oncol; 2007 Jul; 9(3):335-42. PubMed ID: 17504931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
    Kim YH; Goto K; Yoh K; Niho S; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
    Cancer; 2008 Nov; 113(9):2518-23. PubMed ID: 18780323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of thrombocytosis in patients with epithelial ovarian cancer.
    Zeimet AG; Marth C; Müller-Holzner E; Daxenbichler G; Dapunt O
    Am J Obstet Gynecol; 1994 Feb; 170(2):549-54. PubMed ID: 8116711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.